TuHURA Biosciences (NASDAQ:HURA - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
TuHURA Biosciences Price Performance
HURA stock traded up $0.03 during midday trading on Friday, reaching $3.33. The company had a trading volume of 127,458 shares, compared to its average volume of 210,113. TuHURA Biosciences has a 1 year low of $2.84 and a 1 year high of $14.60. The company's 50-day moving average is $4.37.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. Maxim Group began coverage on shares of TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a "buy" rating and a $15.00 target price for the company. RODMAN&RENSHAW raised TuHURA Biosciences to a "strong-buy" rating in a research note on Thursday, December 19th. Finally, Rodman & Renshaw initiated coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price for the company.
Read Our Latest Stock Report on TuHURA Biosciences
Institutional Trading of TuHURA Biosciences
An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,314 shares of the company's stock, valued at approximately $59,000. Hedge funds and other institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Read More
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
